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The establishment of a UK Trophoblastic Disease Registration and
Surveillance Scheme by The Royal College of Obstetricians &
Gynaecologists and The Department of Health in 1973 has been a
great success. Following diagnosis, all patients with gestational
trophoblastic disease (GTD) are registered with and followed up by
one of three centres located at: Weston Park Hospital, Sheffield;
Charing Cross Hospital, London; and Ninewells Hospital, Dundee.
Follow-up takes the form of serial urinary and serum human chori-
onic gonadotrophin (hCG) measurements. Standardized surveil-
lance procedures are adopted nationwide. Patient compliance with
the follow-up programme is very high, which allows the two treat-
ment centres (in Sheffield and London) to adopt stringent treatment
criteria and a conservative treatment philosophy. The UK treatment
centres report high cure rates while exposing the minimal number of
patients possible to cytotoxic chemotherapy (Sheridan et al, 1993).
As standardized surveillance procedures are adopted nation-
wide, there are several differences in practice between the two
treatment centres in terms of definition of persistent GTD, initial
prognostic risk assessment and chemotherapeutic regimens. One
difference is the use of prophylactic chemotherapy for possible
occult central nervous system (CNS) metastases. It is well recog-
nized that choriocarcinoma can metastasize to the brain. Charing
Cross Hospital has previously reported that patients with persistent
GTD and multiple pulmonary metastases or other high-risk
features are at increased risk of CNS metastases. Since 1973 their
patients without evidence of CNS metastases, but with pulmonary
metastases, have been given CNS chemoprophylaxis in the form
of intrathecal (i.t.) methotrexate (12.5 mg) with their first three
cycles of systemic chemotherapy (Althanassiou et al, 1983;
Newlands, 1997). At Weston Park Hospital, however, our manage-
ment differs in that only patients with proven CNS involvement
are treated with CNS chemotherapy. Our policy is to perform a
computerized tomographic (CT) scan of the head and a lumbar
puncture (providing there is no clinical evidence of raised intracra-
nial pressure) to obtain cerebrospinal fluid (CSF) for bhCG levels
in all patients who: (1) are classified ￿high risk￿ at initial prog-
nostic risk assessment by the Sheffield modification of the
Charing Cross Hospital prognostic scoring system (‡ 8 points —
Sheridan et al, 1993); (2) have bhCG levels of 50 000 iu l—1 or
greater, and/or (3) have five or more metastases visible on chest
radiographs/eight or more nodules visible on CT scan of thorax.
Confirmation of CNS involvement is established by imaging
and/or a high (> 1:60) CSF—serum hCG ratio (Bagshawe and
Harland, 1976).
The cure rates for patients with GTD are now high, and so the
focus of patient care has shifted from defining active chemothera-
peutic agents to optimizing therapeutic regimens and minimizing
risk to patients diagnosed with this condition. Our objective in this
study was to evaluate the results of our conservative treatment
approach to putative occult CNS disease in patients with GTD and
pulmonary metastases.
METHODS
Subjects
All patients with GTD registered between 1987 and 1996 were
included in this retrospective analysis. Of 195 patients with persis-
tent GTD who were treated in this time period, 69 had pulmonary
metastases at initial presentation detected by chest radiography
and/or CT of the thorax. The median age of patients in this group
was 27 years (range 16—49 years).
Treatment
Treatment regimens employed at our centre are reported elsewhere
(Fisher and Hancock, 1997). Treatment of patients with established
CNS metastases involves a combination of systemic chemotherapy
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Correspondence to: AM Gillespieand i.t. methotrexate. The systemic therapy comprises a two-arm
regimen, with 7-day intervals between each arm, which is
continued for 2 months after normalization of serum hCG levels.
Arm A consists of methotrexate 1 g m—2 over 24 h with folinic acid
rescue. Arm B consists of dactinomycin 0.5 mg and etoposide
100 mg m—2 6 h apart, daily for 3 days each cycle. Methotrexate
(12.5 mg) i.t. is administered once during arm B of each treatment
cycle and is continued for four injections after the CSF—serum
ratios have returned to normal. A combination of high-dose intra-
venous methotrexate and i.t. methotrexate is used to ensure
adequate CNS penetration of this drug (Shapiro et al, 1975).
RESULTS
Pulmonary metastases
Sixty-nine patients were identified with pulmonary metastases.
Chest radiography and CT of the thorax were performed in 63
cases and CT only in the remaining six cases. Among the 63
patients in whom both investigations were performed, 36 had
metastases detected by both modalities and 27 had metastases
detectable on CT only.
Prognostic risk scores, treatment and follow-up
Patients were assessed according to modified Charing Cross criteria
(Sheridan et al, 1993). The median risk score was 6 (range 1—23).
Fifty-one patients were classified as having low-risk disease and 18
as having high-risk disease. Thirty-one low-risk patients were
successfully treated with first-line therapy (low-dose methotrexate);
19 required second-line chemotherapy with dactinomycin and etopo-
side. Treatment is ongoing in one patient. Of the 18 high-risk
patients, 11 were cured with first-line therapy (methotrexate/dactino-
mycin/etoposide), three with second-line therapy (cisplatin/etopo-
side/cyclophosphamide) and one with the CNS regimen (see above);
one further patient was inappropriately but successfully treated with
the low-risk regimen. Two patients in the high-risk prognostic group
have died from disease. Sixty-six patients have successfully
completed their treatment with a median follow up of 62 months
(range 14—128 months).
CNS metastases
Three patients with persistent GTD received treatment for CNS
metastasis. The first patient had an initial risk score of 7 and was
classified as having low-risk disease. Chest radiography was nega-
tive but CT scanning showed multiple small pulmonary metastases.
This patient￿s prognosis was compromised by late presentation and
non-compliance with follow-up and she subsequently developed a
solitary cerebral metastasis, which was treated with neurosurgery,
CNS chemotherapy and on further relapse with high-dose chemo-
therapy. Treatment is ongoing for active, probably drug-resistant,
pulmonary disease. The second patient had disseminated post-
partum choriocarcinoma with CNS involvement at presentation and
was successfully treated with nine cycles of the regimen described
above. She is alive and disease free at 36 months. The final patient
had a placental site trophoblastic tumour with CNS involvement and
died of disease despite multiple therapeutic interventions.
DISCUSSION
There are differing policies world-wide for the treatment of poten-
tial and established CNS disease in GTD. In the UK, surgical and
chemotherapeutic treatment modalities are generally used in
patients with established CNS metastases (Althanassiou et al,
1983; Rustin et al, 1989). In contrast, GTD has been shown to be
radiosensitive (Brace, 1968), and elsewhere the policy of whole-
brain irradiation in conjunction with chemotherapy has met with
some success (Weed and Hammond, 1980; Yordan et al, 1987;
Evans et al, 1995). However, CNS metastasis still causes signifi-
cant mortality, and those in this patient group have a poorer prog-
nosis than the rest of the GTD patient population.
In view of the difficulties inherent in the treatment of estab-
lished CNS disease it would seem logical to attempt to identify
patients at risk of CNS metastases and try to prevent this problem
arising. This is the basis of the policy of CNS prophylaxis used
at Charing Cross Hospital. However, the administration of i.t.
chemotherapy is not without risk and should only be recom-
mended when it is absolutely necessary and of proven value. This
study suggests that prophylactic i.t. methotrexate is unnecessary in
patients with pulmonary metastases. This study is supported by
published data from North America which demonstrate that the
cure rate for patients with pulmonary metastases not receiving
CNS chemoprophylaxis approaches 100% (Du Beshter et al, 1991;
Soper et al, 1994; Roberts and Lurain, 1996).
Also, it is clear from this retrospective analysis that, where a
successful surveillance scheme is in operation, patients with
persistent GTD necessitating chemotherapy are generally identi-
fied before widespread pulmonary metastasis occurs. Of the 195
patients treated during the study time period, only 69 (35%) had
pulmonary metastases.
In conclusion, restriction of IT treatment to those patients with
established CNS disease appears to be safe and effective. With the
low incidence of intracranial disease in this group of patients, the
impact of IT chemoprophylaxis is likely to be small and has to be
weighed against morbidity associated with such therapy.
ACKNOWLEDGEMENTS
The authors would like to thank Mrs CR Radstone and Dr PC
Lorigan for their assistance in the conduct of this study.
REFERENCES
Althanassiou A, Newlands ES, Rustin GJS, et al (1983) Central nervous system
metastases of choriocarcinoma: 23 years experience at Charing Cross Hospital.
Cancer 52: 1728—1735
Bagshawe KD and Harland S (1976) Immunodiagnosis and monitoring of
gonadotrophin producing metastases in the central nervous system. Cancer 38:
112—118
Brace KC (1968) The role of irradiation in the treatment of metastatic trophoblastic
disease. Radiology 91: 540—544
Du Beshter B, Berkowitz RS, Goldstein DP and Bernstein MR Management of low
risk metastatic gestational trophoblastic tumour. J Reprod Med 36: 36—39
Evans AC, Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez GC and Hammond
CB (1995) Gestational trophoblastic disease metastatic to the central nervous
system. Gynecol Oncol 59(2): 226—230
Fisher PM and Hancock BW (1997) Gestational trophoblastic diseases and their
treatment. Cancer Treat Rev 23: 1—6
Newlands ES (1997) Investigation and treatment of patients with persistent
Gestational Trophoblastic Disease and Gestational Trophoblastic Tumors in the
UK. In Gestational Trophoblastic Disease, Hancock BW, Newlands ES and
Berkowitz RS (eds), pp. 173—190. Chapman & Hall: London
Roberts JP and Lurain JR (1996) Treatment of low risk metastatic gestational
trophoblastic tumour with single-agent chemotherapy. Am J Obstet Gynecol
174: 1917—1924
Rustin GJS, Newlands ES, Begent RHJ, Dent J and Bagshawe KD (1989) Weekly
alternating etoposide, methotrexate and actinomycin/vincristine and
GTD and CNS prophylaxis 1271
British Journal of Cancer (1999) 79(7/8), 1270–1272 © Cancer Research Campaign 19991272 AM Gillespie et al
British Journal of Cancer (1999) 79(7/8), 1270–1272 © Cancer Research Campaign 1999
cyclophosphamide chemotherapy for the treatment of CNS metastases of
choriocarcinoma. J Clin Oncol 7: 900—903
Shapiro WR, Young DR and Mehta BM (1975) Distribution in cerebrospinal fluid
after intravenous ventricular and lumbar injections. NEJM 293: 161—166
Sheridan E, Hancock BW, Smith SC, Dorreen MS, Neal FE, Pennington GW and
Millar DR (1993) Gestational trophoblastic disease: experience of the Sheffield
(United Kingdom) supraregional screening and treatment service. Int J Oncol
3: 149—155
Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G and Hammond CB (1994).
Five-day methotrexate for women with metastatic gestational trophoblastic
disease. Gynecol Oncol 54: 76—79
Weed JC and Hammond CB (1980) Cerebral metastatic choriocarcinoma: intensive
therapy and prognosis. Obstet Gynecol 55: 89—94
Yordan EL, Schlaerth J, Gaddis O and Morrow CP (1987) Radiation therapy in the
management of gestational choriocarcinoma metastatic to the central nervous
system. Obstet Gynecol 69: 627—630